Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the first patient in the ADVENT-AML Phase 1B clinical trial in Acute Myeloid Leukemia (AML) has received treatment with CHM 0201 in combination with azacitidine and venetoclax.
The ADVENT-AML (NCT05834244) Phase 1B clinical trial is an investigator-initiated study currently open to enrollment at The University of Texas MD Anderson Cancer Center under principal investigator Abhishek Maiti MD, Assistant Professor in the Department of Leukemia.
The study is the first trial to evaluate the synergy of NK cell therapy with the current standard of care for AML, azacitidine and venetoclax.
The study is designed to enrol up to 20 subjects with newly diagnosed AML who are not eligible for intensive chemotherapy or allogeneic stem cell transplant, following a dose confirmation cohort assessing the safety of this novel combination treatment in subjects with relapsed or refractory AML.
Recently, it was announced that CHM 0201 cells completed manufacturing and release testing and were provided to MD Anderson to support the ADVENT-AML Phase 1B clinical trial. The CHM 0201 NK cells were manufactured at the Cellular Therapy Integrated Services Laboratory at Case Western Reserve University, where the CHM 0201 cells were developed.
“We are very happy to report this progress in the ADVENT-AML clinical trial,” said Jason B Litten MD, chief medical officer of Chimeric Therapeutics. “The novel combination of CHM 0201 with the standard of care in AML treatment has the potential to transform frontline therapy and enhance outcomes for AML patients.”
